24 results for author:"Penault-Llorca F." in Literature citations
Results Customize
| Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. Valent A., Penault-Llorca F., Cayre A., Kroemer G. Cancer Genet 206:37-41(2013) · Mapped (8) |
| FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Ladoire S., Mignot G., Dalban C., Chevriaux A., Arnould L., Rebe C., Apetoh L., Boidot R., Penault-Llorca F., Fumoleau P. et al. Ann. Oncol. 23:2552-2561(2012) · Mapped (5) |
| Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. Thariat J., Etienne-Grimaldi M.C., Grall D., Bensadoun R.J., Cayre A., Penault-Llorca F., Veracini L., Francoual M., Formento J.L., Dassonville O. et al. Clin. Cancer Res. 18:1313-1322(2012) · Mapped (19) |
| Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. El Guerrab A., Zegrour R., Nemlin C.C., Vigier F., Cayre A., Penault-Llorca F., Rossignol F., Bignon Y.J. PLoS ONE 6:e25080-e25080(2011) · Mapped (28) |
| Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Xie Z.M., Li L.S., Laquet C., Penault-Llorca F., Uhrhammer N., Xie X.M., Bignon Y.J. Cancer 117:3112-3117(2011) · Mapped (6) |
| Zinc-alpha2-glycoprotein: a new biomarker of breast cancer? Dubois V., Delort L., Mishellany F., Jarde T., Billard H., Lequeux C., Damour O., Penault-Llorca F., Vasson M.P., Caldefie-Chezet F. Anticancer Res. 30:2919-2925(2010) · Mapped (2) |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P. et al. Lancet Oncol. 11:753-762(2010) · Mapped (22) |
| Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Laurent-Puig P., Cayre A., Manceau G., Buc E., Bachet J.B., Lecomte T., Rougier P., Lievre A., Landi B., Boige V. et al. J. Clin. Oncol. 27:5924-5930(2009) · Mapped (33) |
| Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. Jacobs B., De Roock W., Piessevaux H., Van Oirbeek R., Biesmans B., De Schutter J., Fieuws S., Vandesompele J., Peeters M., Van Laethem J.L. et al. J. Clin. Oncol. 27:5068-5074(2009) · Mapped (8) |
| Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. Gomez-Roca C., Raynaud C.M., Penault-Llorca F., Mercier O., Commo F., Morat L., Sabatier L., Dartevelle P., Taranchon E., Besse B. et al. J Thorac Oncol 4:1212-1220(2009) · Mapped (23) |
| Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. Chene G., Penault-Llorca F., Le Bouedec G., Mishellany F., Dauplat M.M., Jaffeux P., Aublet-Cuvelier B., Pouly J.L., Dechelotte P., Dauplat J. Int. J. Gynecol. Cancer 19:65-72(2009) · Mapped (18) |
| Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. Leary A.F., Hanna W.M., van de Vijver M.J., Penault-Llorca F., Ruschoff J., Osamura R.Y., Bilous M., Dowsett M. J. Clin. Oncol. 27:1694-1705(2009) · Mapped (8) |
| Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. Bibeau F., Lopez-Crapez E., Di Fiore F., Thezenas S., Ychou M., Blanchard F., Lamy A., Penault-Llorca F., Frebourg T., Michel P. et al. J. Clin. Oncol. 27:1122-1129(2009) · Mapped (14) |
| Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Jarde T., Caldefie-Chezet F., Damez M., Mishellany F., Penault-Llorca F., Guillot J., Vasson M.P. Oncol. Rep. 19:905-911(2008) · Mapped (9) |
| p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Bidard F.C., Matthieu M.C., Chollet P., Raoefils I., Abrial C., Domont J., Spielmann M., Delaloge S., Andre F., Penault-Llorca F. Ann. Oncol. 19:1261-1265(2008) · Mapped (33) |
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouche O., Landi B., Louvet C. et al. J. Clin. Oncol. 26:374-379(2008) · Mapped (8) |
| HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. Tuefferd M., Couturier J., Penault-Llorca F., Vincent-Salomon A., Broet P., Guastalla J.P., Allouache D., Combe M., Weber B., Pujade-Lauraine E. et al. PLoS ONE 2:e1138-e1138(2007) · Mapped (5) |
| Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Arnould L., Arveux P., Couturier J., Gelly-Marty M., Loustalot C., Ettore F., Sagan C., Antoine M., Penault-Llorca F., Vasseur B. et al. Clin. Cancer Res. 13:6404-6409(2007) · Mapped (8) |
| Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk category. Gimbergues P., Dauplat M.M., Cayre A., Durando X., Le Bouedec G., Finat-Duclos F., Portefaix G., Kwiatkowski F., Dauplat J., Penault-Llorca F. et al. Eur J Surg Oncol 33:16-22(2007) · Mapped (6) |
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Cote J.F., Tomasic G., Penna C., Ducreux M. et al. Cancer Res. 66:3992-3995(2006) · Mapped (18) |
| Patterns of P-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats. Balayssac D., Cayre A., Authier N., Bourdu S., Penault-Llorca F., Gillet J.P., Maublant J., Eschalier A., Coudore F. J. Peripher. Nerv. Syst. 10:301-310(2005) · Mapped (1) |
| Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Caldefie-Chezet F., Damez M., de Latour M., Konska G., Mishellani F., Fusillier C., Guerry M., Penault-Llorca F., Guillot J., Vasson M.P. Biochem. Biophys. Res. Commun. 334:737-741(2005) · Mapped (5) |
| Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Lakhani S.R., Manek S., Penault-Llorca F., Flanagan A., Arnout L., Merrett S., McGuffog L., Steele D., Devilee P., Klijn J.G. et al. Clin. Cancer Res. 10:2473-2481(2004) · Mapped (18) |
| The human FGF9 gene maps to chromosomal region 13q11-q12. Mattei M.G., Penault-Llorca F., Coulier F., Birnbaum D. Genomics 29:811-812(1995) |